{"links":{"feed":"https://www.erudio.com/reports/kc-wise-nct05427383/feed.json","html":"https://www.erudio.com/reports/kc-wise-nct05427383","json":"https://www.erudio.com/reports/kc-wise-nct05427383.json","markdown":"https://www.erudio.com/reports/kc-wise-nct05427383.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"kc-wise-nct05427383"}},"request":"https://www.erudio.com/contact?report=kc-wise-nct05427383"},"offer":{"cited_clinicians":7,"cited_commentary_sources":25,"verified_hcp_statements":77,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":12},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"kc-wise-nct05427383"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=kc-wise-nct05427383","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/kc-wise-nct05427383","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 77 verified statements · 26 from 7 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T06:00:39.182667Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":24,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":19,"title":"Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC"},{"claim_count":24,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":20,"title":"Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC"},{"claim_count":19,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":16,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":11,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":17,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":16,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":7,"title":"Clinical readiness, global validation and HER2 reassessment"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":7,"title":"Post-trastuzumab alternatives, access and HER2-treatment sequencing"},{"claim_count":20,"coverage":"discussed","id":"A3","source_count":9,"title":"Dual-epitope rationale and drug-class terminology"},{"claim_count":8,"coverage":"discussed","id":"A4","source_count":1,"title":"Survival-curve interpretation and communication"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":3,"title":"Chemotherapy-free extrapolation outside the tested regimen"},{"claim_count":4,"coverage":"discussed","id":"A6","source_count":1,"title":"Lower-HER2 predictions, testing labels and patient support"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":7,"cited_clinicians":7,"cited_clinicians_by_role":{"physician":1,"physician, Gastroenterology":1,"physician, Medical oncology":5},"cited_physicians":7,"cited_sources":25,"claims_by_expression_type":{"comparison":5,"experience":1,"interpretation":33,"opinion":20,"restatement":6,"uncertainty":1,"unspecified":11},"claims_by_kind":{"source_observation":77},"clinician_statements":26,"evidence_units":69,"findings":8,"organisational_accounts":2,"people_cited":13,"people_identity_verified":12,"people_total":13,"screened_sources":43,"verified_claims":77},"findings_index":[{"cited_clinicians":3,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":10},"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":5,"passages":9,"sources":7,"sources_by_kind":{"commentary":7}},"title":"KC-WISE: where speakers split on readiness to change practice","title_holders":{"cited_claim_ids":["claim-c42f2d0b25d6b092b99e","claim-b3e53c884b00eb477ac3","claim-a7447e8d0a531145eb44","claim-38a5559bbd1f083ee4c4","claim-debbec8447aa7860c675","claim-31be75919f5dd36b368d","claim-d7d2507a36d62aa5123f"],"clinicians":false,"holders":5,"sides":[{"cited_claim_ids":["claim-c42f2d0b25d6b092b99e"],"holders":1},{"cited_claim_ids":["claim-b3e53c884b00eb477ac3","claim-a7447e8d0a531145eb44","claim-38a5559bbd1f083ee4c4","claim-debbec8447aa7860c675","claim-31be75919f5dd36b368d","claim-d7d2507a36d62aa5123f"],"holders":4}],"speakers":5,"view":"split"},"evidence_line":"11 statements from 5 speakers in 7 sources","holder_line":"5 of the 5 named speakers in this finding take a side on this question: 1 on one side, 4 on the other"},{"cited_clinicians":2,"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"KC-WISE results: how speakers weigh the chemotherapy-only comparator","title_holders":{"cited_claim_ids":["claim-49631753d43f3de93c87","claim-6272a6989aea4353831a","claim-46a339e60ab9390abd86"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"5 statements from 3 speakers in 3 sources","holder_line":"3 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":3,"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":0,"views":6},"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"KN026 beyond T-DXd: what speakers say","evidence_line":"8 statements from 4 speakers in 5 sources"},{"cited_clinicians":6,"id":"F4","structure":{"claims":20,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":6,"views":12},"limitations":3,"links":{"context":0,"support":24},"ma_question":true,"named_voices":11,"passages":20,"sources":17,"sources_by_kind":{"commentary":15,"media":2}},"title":"KC-WISE safety: where speakers split on added toxicity versus chemotherapy alone","title_holders":{"cited_claim_ids":["claim-28a3e37b04523457b4fd","claim-01fa2ccacd64f88fd245","claim-8ad1429414e64672ac27","claim-1848d1bfdf9be49d59ad","claim-75c2608b5d8fc4ef1c3f","claim-871d692c3d31f537ace5","claim-b3e53c884b00eb477ac3","claim-771f333077181675c404","claim-4fbb5f241f4739f4499f","claim-3a4a109ba3f7f7dbd748","claim-26303b49697b5f12ffb5","claim-1d36a930cfd1281db667","claim-294badb21a8759d89bd6","claim-deaf026da79f3378b60e"],"clinicians":false,"holders":8,"sides":[{"cited_claim_ids":["claim-28a3e37b04523457b4fd","claim-01fa2ccacd64f88fd245"],"holders":2},{"cited_claim_ids":["claim-8ad1429414e64672ac27","claim-1848d1bfdf9be49d59ad","claim-75c2608b5d8fc4ef1c3f","claim-871d692c3d31f537ace5","claim-b3e53c884b00eb477ac3","claim-771f333077181675c404","claim-4fbb5f241f4739f4499f","claim-3a4a109ba3f7f7dbd748","claim-26303b49697b5f12ffb5","claim-1d36a930cfd1281db667","claim-294badb21a8759d89bd6","claim-deaf026da79f3378b60e"],"holders":7}],"speakers":11,"view":"split"},"evidence_line":"20 statements from 11 speakers in 17 sources, 2 of them podcasts or videos","holder_line":"8 of the 11 named speakers in this finding take a side on this question: 2 on one side, 7 on the other, 1 on both"},{"cited_clinicians":0,"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":7},"limitations":2,"links":{"context":2,"support":12},"ma_question":true,"named_voices":1,"passages":11,"sources":1,"sources_by_kind":{"media":1}},"title":"KC-WISE curves: why a speaker looks beyond medians for long-term outcomes","title_holders":{"cited_claim_ids":["claim-e64f7b55b5f2b039042d","claim-879e1f087901623bca60","claim-6b9dfed8dd8d26b70886"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"8 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":4,"id":"F6","structure":{"claims":31,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":7,"views":22},"limitations":3,"links":{"context":1,"support":34},"ma_question":true,"named_voices":10,"passages":22,"sources":17,"sources_by_kind":{"commentary":15,"media":2}},"title":"Dual HER2 targeting: what most speakers highlight, while some use ADC terms","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-871d692c3d31f537ace5","claim-45f42cc071233a998b50","claim-8c489eb0171869252ed0","claim-931ea225f33df987bc74"],"clause":"some use ADC terms","holders":2},"cited_claim_ids":["claim-70dde681455d1b2db274","claim-75c2608b5d8fc4ef1c3f","claim-34d638095569bed05288","claim-e0b861bce10af404ad29","claim-abff797046efc71396df","claim-c42f2d0b25d6b092b99e","claim-d7d2507a36d62aa5123f","claim-a23e3bc6ae96c73f7579","claim-45f42cc071233a998b50","claim-0c0662449bde5e1dcaaf","claim-8c489eb0171869252ed0","claim-ea079c14b92f0f9e1fea","claim-30631b6472acaf928675","claim-445fc2ab64a6560aeb22","claim-bc96f83ae34eec64c177"],"clinicians":false,"holders":9,"speakers":10,"view":"reading"},"evidence_line":"31 statements from 10 speakers in 17 sources, 2 of them podcasts or videos","holder_line":"9 of the 10 named speakers in this finding hold this view; 2 of them hold its caveat, “some use ADC terms”"},{"cited_clinicians":1,"id":"F7","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":4},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Chemotherapy with KN026: a speaker thinks it is probably unnecessary in routine care","title_holders":{"cited_claim_ids":["claim-a13bcdbf61c01b9f8268"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 3 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":8,"sources":1,"sources_by_kind":{"media":1}},"title":"KN026 at lower HER2 expression: why a speaker expects activity","title_holders":{"cited_claim_ids":["claim-364318330da5e3118b37"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From finding F1 (11 statements from 5 speakers in 7 sources)","cited_claim_ids":["claim-1848d1bfdf9be49d59ad","claim-b3e53c884b00eb477ac3","claim-a7447e8d0a531145eb44","claim-e765a2bc6613d4847821","claim-38a5559bbd1f083ee4c4","claim-debbec8447aa7860c675","claim-e0b861bce10af404ad29","claim-c42f2d0b25d6b092b99e","claim-31be75919f5dd36b368d","claim-f3a560e0b7c2e8276dfe","claim-d7d2507a36d62aa5123f"],"finding_ids":["F1"],"question":"What do clinicians need from mature overall-survival follow-up and global validation to decide whether KC-WISE’s anbenitamab plus chemotherapy should change practice after trastuzumab failure in HER2-positive gastric/GEJ cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"X accounts disagree over whether KC-WISE is ready to change practice"},{"id":"section-2","level":2,"title":"X accounts question how the chemotherapy-only control shapes the apparent benefit"},{"id":"section-3","level":2,"title":"One X account tentatively keeps T-DXd second line while considering selective later-line KN026 use"},{"id":"section-4","level":2,"title":"Speakers range from describing safety as comparable to highlighting added toxicity"},{"id":"section-5","level":2,"title":"One video speaker argues that medians can understate the perceived long-term benefit"},{"id":"section-6","level":2,"title":"Whether dual-epitope HER2 targeting can overcome trastuzumab resistance"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"One video speaker suggests chemotherapy may be unnecessary in routine care"},{"id":"section-9","level":3,"title":"One video speaker predicts activity at lower HER2 expression"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":10},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":11}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":11},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":12}],"id":"T2","label":"Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":13},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":8}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":4}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":17},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":4}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T06:00:39.182667Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T06:20:41Z","record_hash":"8c8c93b9e5ac9672d89071b3bb15b90d31a370c08430ee4506f2e8ad77d9f407","release_hash":"036d532bb7b86680e2d49f8c92b082e2e6aca5df96075cc1553e271d3d86cd14","report_id":"erudio-nct05427383","run_id":"1e8f234e-0c38-4a98-967a-517dd4653ac2","schema_version":"5.0","slug":"kc-wise-nct05427383","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist reads KC-WISE as a signal for changing care, citing benefit from continued HER2 targeting; another considers the interim overall-survival data too immature for that judgment. A physician leans toward T-DXd for now, while considering later anbenitamab for patients with lung disease. Differences among secondary accounts remain unresolved without an original results publication in the sources reviewed. The sources place interim results at ESMO 2025 and the updated OS analysis at ESMO 2026.","examples":[],"meta_description":"43 sources screened · 77 verified statements (26 from clinicians verified by NPI or staff page) from 25 sources · 8 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T06:20:41Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-19T07:07:17Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":43},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on the survival-benefit versus toxicity trade-off of antibody plus chemotherapy after first-line treatment.","1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.","25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 44 sources about other trials or topics are not included.","This report characterizes the sources reviewed for this edition, not all HCP discussion or the prevalence of any opinion. Repeated posts and reposts are not independent endorsements.","Potentially relevant discussion may be missing where the trial or KN026 is not named or is described differently. One X conversation could not be read, and part of a video was not fully assessed.","No full protocol or original trial results publication is included. Linked article information and secondary summaries cannot independently resolve disagreements about study conduct or results.","Authors report different response rates, event definitions and analysis populations. These accounts are kept distinct rather than pooled into one results summary.","Some comments about survival-curve interpretation, stratification and Canadian prescribing have no identifiable speaker. They cannot be assigned to a named speaker or counted as independent agreement.","Product-specific regulatory information is incomplete. Statements about historical approval, availability or prescribing remain attributed accounts, not independently established regulatory conclusions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-23","start":"2025-10-16"},"retrieval_snapshot":"2026-11-19T05:22:26.137694Z","timeline":[{"count":13,"week":"2025-W42"},{"count":1,"week":"2025-W47"},{"count":4,"week":"2026-W04"},{"count":3,"week":"2026-W09"},{"count":1,"week":"2026-W23"},{"count":3,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05427383:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05427383:context","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385044478249750528","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971920587871473963:571ab4e2-e7b6-4263-a039-2f6d14916f4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972805388052390122:78c37dfc-be08-4720-b612-63f417cb2a34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978963821525111289:2e73b888-b9b4-4441-a237-cb1b10bd3ba5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979094907164987742:a59d4204-c446-4c0b-bd1a-647177edfb66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979103337459892337:d3888ea7-f06a-42b0-b767-263098d68580","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979172726867685854:b7389856-42c7-40ac-a229-e348bd63cd50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173495759163507:84bddfc2-885c-4063-a9b7-91fdac1ba01d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173787611304393:7acfe8f6-0da5-4833-9e8c-a40d3b31c73a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173897359552651:28aceb0b-706b-41cc-9dce-9508ec9e924d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979174855632126312:d9cfc9b8-d7c0-4b63-8acc-5a9b161722af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979175978262831246:fee530f5-c55f-4a5d-9b1c-e76237ae5d55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979181578682089475:a9c4282d-99f5-4610-9c36-6a4f164f19ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979268270625890718:643f9cf2-4f29-4089-9ce9-d650c5bab813","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979276665764319264:07af806f-3ba5-40b5-a920-7a3bdfde9fb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979277006412890280:c0b8e97b-8f67-4fdc-b0a2-7c4dea318113","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2004251037461323779:37d6552a-6396-4c31-ab72-3070435e2a4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013547443401486731:a2053fe7-6c7c-4417-b045-6bb2a6ae8dc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013584920321405260:56409cb3-9b7c-457b-bb20-7768542cd136","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013605094512898294:1ffed55f-b094-4b85-b53e-7cabb175d6ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013709865340842293:9e4957bf-c5f8-4a03-a2ed-985bcf8fc24d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013911245540221209:cdee54c9-cb0f-490e-b94e-a024f40d1fe6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014289102888214584:9bd1e5e7-d30d-44ba-ad3b-090731849140","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016571984298332650:4ed97b0d-3a97-4a86-90e7-3e2829afd158","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026229167642067333:7b1474ea-140a-4a1b-b3fc-6761ccfb4a08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026376475436323263:d0ccb9b3-b718-45a4-8f6b-125c5b7e5598","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063075965694030024:3352a8f9-ec7e-46af-81be-6c52909c4c15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:7a9f6256-9c22-449a-a219-2d895ac28e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105990928217334044:c005e9b7-687f-4ccb-8337-1162e1a8d6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108478573388398607:a49fa46f-8d26-4e0b-8440-dedf077c7225","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:625008de-2bc6-4231-857f-9831793f24da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902368220287215:f730ae81-aa09-487b-9d1c-337436f579c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113280507975008719:53255843-2f28-4715-8708-367ff16e4483","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113638192481960446:c4e05b03-a159-435c-b318-d660db7e9189","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113638796608655703:f1f25788-64fa-4451-93be-bb66f4397776","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113666554072027558:029c4a3f-8d0a-4045-ab76-570846f6d745","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113678471662592007:48298c44-ddf4-43d4-83b9-57a00bf90a9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115488476225266094:89284dfc-7c8f-43cc-83e7-80c7555d1f5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115764765889008074:e8e8d0fb-eed1-41a8-ba9b-f2d5496fc0c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116599499321696716:b9066dd4-f26d-4de9-a967-68272393bd76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116955420418072753:af6d0852-1445-42b8-98f7-60fea3076de8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FjWauAvP2TE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JJJZQfr1drU","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":40,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":43},"count":43,"evidence_window":{"end":"2026-11-01","start":"2025-09-27"},"retrieval_snapshot":"2026-11-19T05:22:26.137694Z","timeline":[{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W41"},{"count":14,"week":"2025-W42"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W52"},{"count":6,"week":"2026-W04"},{"count":1,"week":"2026-W05"},{"count":3,"week":"2026-W09"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":6,"week":"2026-W43"},{"count":4,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":43,"x_video":0,"youtube":33}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: kn026/placbo injection","status":"unmapped"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"}],"indications":[{"reason":"Unmapped registry condition: Stomach Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Gastric cancer","slug":"gastric-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KC-WISE","aliases":["KC-WISE","KN026-001","KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy."],"brief_title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Stomach Cancer"],"display_condition":"HER2-positive advanced gastric cancer after failed first-line therapy","display_interventions":[["KN026"]],"enrollment":{"count":286,"type":"ESTIMATED"},"interventions":[{"name":"KN026/Placbo Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Paclitaxel Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Docetaxel Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Irinotecan Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05427383","official_title":"A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2025-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"The time from the first dose of study treatment to the date of documented disease","measure":"Progression Free Survival (PFS) according to RECIST 1.1 by IRC","timeFrame":"Up to 2.5 years"},{"description":"The time from the first dose of study treatment until the date of death from any cause","measure":"Overall Survival (OS) according to RECIST 1.1 by IRC","timeFrame":"Up to 2.5 years"}],"registered_date":{"date":"2022-06-22","type":"ACTUAL"},"registry_last_updated":"2023-12-19","registry_url":"https://clinicaltrials.gov/study/NCT05427383","short_name":"KC-WISE","short_name_basis":"canonical_name","sponsor":"Shanghai JMT-Bio Inc.","start_date":{"date":"2022-04-07","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"KN026-001","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}